Afuco™ Anti-Human TNFSF14 ADCC Therapeutic Antibody (SAR252067), ADCC Enhanced

Cat. No.: AFC-615CL
This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

### Product Overview
Anti-TNFSF14 ADCC Enhanced Antibody (SAR252067) is an ADCC enhanced antibody produced by our Afuco™ platform. SAR 252067 is an anti-LIGHT fully human monoclonal antibody that is being developed for the treatment of ulcerative colitis and crohn’s disease.

### Host Species
Human

### Target
TNFSF14

### Derivation
Human

### Species Reactivity
Human

### Type
ADCC enhanced antibody

### Expression Host
Fucosyltransferse-engineered cell line

### Purity
>90% assessed by SDS-PAGE

### Applications
FuncS

### Application Notes
The antibody was validated for Function Assay. For details, refer to Published Data.

### Storage
≤6 months at 4°C; ≥6 months at -20°C.

### Related Disease
Autoimmune Diseases; Crohn's Disease; Ulcerative Colitis

BACKGROUND
### Introduction
SAR 252067 is an anti-LIGHT fully human monoclonal antibody that is being developed for the treatment of ulcerative colitis and Crohn's disease.

### Alternative Names
TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; LTg; TR2; CD258; HVEM; LIGHT; tumor necrosis factor ligand superfamily member 14; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>8740</th>
</tr>
</thead>
<tbody>
<tr>
<td>UniProt ID</td>
<td>Q43557</td>
</tr>
</tbody>
</table>